Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

A phase II study evaluating the efficacy and safety of imetelstat in patients with advanced myelodysplastic neoplasms or AML failing HMA-based therapy – interim analysis results of the IMpress study

View Full Paper
Ask AI
Bookmark
Share

Authors

LALionel AdèsAGAlice GarnierUPUwe Platzbecker

Discussion

Loading...

Member takes

Overview

Phase II trial reports limited efficacy of imetelstat in advanced MDS or AML, highlighting poor outcomes after HMA treatment.

Key Points

  • Median progression-free survival was 69 days for the first cohort and 92 days for the second cohort, indicating treatment challenges.
  • Imetelstat was evaluated in patients failing HMA therapy, with low response rates observed despite increased exposure.
  • Analysis of serious adverse events showed no new toxicity signals with increased dosing intervals for imetelstat treatment.
  • These findings underscore the need for alternative therapeutic approaches in managing advanced myelodysplastic neoplasms and AML.

Cite This Study

Adès et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d882https://doi.org/10.1182/blood-2025-5155
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study2026 · 1 citations
  2. 2Improvemf: Phase 1b trial of imetelstat plus ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis2025 · 2 citations
  3. 3Long-term outcomes from the randomized, double-blind, placebo (PBO)-controlled, phase 3 imerge trial of imetelstat (IME) for lower-risk myelodysplastic syndromes (LR-MDS)2025 · 1 citations
  4. 4Azacitidine and luspatercept metronomic therapy for intermediate- to high-risk myelodysplastic syndrome: A prospective single-center phase II clinical trial2025
  5. 5PyramIDH: A phase 3 study of ivosidenib monotherapy or azacitidine monotherapy in patients with mutant isocitrate dehydrogenase 1 myelodysplastic syndromes who have not received prior hypomethylating agent therapy2025